Sonam Kundeling, MD
Nephrology · Albuquerque, NMNPI 1326044579
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,184, 9.4 times the $126 reported in 2019.
Across 172 payments — averaging $25.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nxstage Medical, Inc.$910
- Amgen$572
- Bayer$363
- Vifor Pharma, Inc.$339
- AstraZeneca$274
- Calliditas Therapeutics US Inc.$247
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,23398%
- Education$792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nxstage Medical, Inc. | 18 | $910 |
| Amgen(2 entities) | 16 | $572 |
| Bayer | 16 | $363 |
| Vifor Pharma, Inc. | 20 | $339 |
| AstraZeneca(2 entities) | 17 | $274 |
| Calliditas Therapeutics US Inc. | 11 | $247 |
| Travere Therapeutics, Inc. | 8 | $230 |
| Daiichi Sankyo Inc. | 12 | $200 |
| Otsuka America Pharmaceutical, Inc. | 7 | $141 |
| Fresenius USA Marketing, Inc. | 5 | $117 |
| Medtronic | 2 | $117 |
| GSK | 7 | $103 |
| Outset Medical Inc | 1 | $101 |
| Aurinia Pharma U.S., Inc. | 5 | $100 |
| Novo Nordisk | 5 | $96 |
| Novartis | 5 | $91 |
| Akebia Therapeutics Inc | 3 | $54 |
| Apellis Pharmaceuticals, Inc. | 2 | $46 |
| Johnson & Johnson | 3 | $45 |
| Ultragenyx Pharmaceutical Inc. | 2 | $39 |
| Veloxis Pharmaceuticals, Inc. | 1 | $32 |
| Sanofi | 1 | $23 |
| Ascendis Pharma Endocrinology Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Covidien LP | 1 | $15 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NXSTAGE SYSTEM ONE$433
- LIBERTY SELECT CYCLER$324
- Kerendia$124
- Tavneos$112
- PUREFLOW SL$109
How this compares
$4,312 in reported general payments places this provider in the 75th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 125 | $101,293 |
| KerendiaFinerenone | 27 | $32,530 |
| AuryxiaFerric Citrate | 17 | $30,213 |
| JardianceEmpagliflozin | 19 | $17,296 |
| Cinacalcet Hcl | 24 | $8,943 |
| Sevelamer Carbonate | 31 | $4,673 |
| Everolimus | 12 | $4,254 |
| Tacrolimus | 33 | $2,437 |
| Calcitriol | 120 | $2,362 |
| Losartan Potassium | 154 | $1,756 |
| Potassium Chloride | 69 | $1,297 |
| Potassium Citrate ErPotassium Citrate | 18 | $1,225 |
| Bumetanide | 32 | $1,183 |
| Furosemide | 109 | $1,168 |
| Nifedipine ErNifedipine | 44 | $1,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $274 | $101,293125 claims |
| BayerKerendia | $363 | $32,53027 claims |
| Akebia Therapeutics IncAuryxia | $54 | $30,21317 claims |
| Boehringer IngelheimJardiance | $15 | $17,29619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 68 nephrology providers in New Mexico.
Other nephrology in Albuquerque
- Satyaki BanerjeeAlbuquerque$260K
- Christos ArgyropoulosAlbuquerque$32K
- Arun RajasekaranAlbuquerque$32K
- George Vasquez RiosAlbuquerque$25K
- Jayant KumarAlbuquerque$12K
- Luis Madera MarinAlbuquerque$7K
- Hector CastroAlbuquerque$7K
- Chudi AdiAlbuquerque$7K
- Dale EricksonAlbuquerque$6K
- Lei ChenAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.